Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Pro

Showing results (81-90 of 187) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortiumSonali M Smith, Koen van Besien, Theodore Karrison, et al.
Leukemia & Lymphoma|August 11, 2025
Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphomaEmily R Gordon, Seda Tolu, Brigit A Lapolla, et al.
British Journal of Haematology|July 5, 2007
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang, Luis Fayad, Peter McLaughlin, et al.
Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Yasuhiro Oki, Barbara Pro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
American Journal of Hematology|March 22, 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registryRobert N Stuver, Niloufer Khan, Marc Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantationMaricer P Escalón, Richard E Champlin, Rima M Saliba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsFarhad Ravandi, Ahmed Aribi, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study databasePhilippe Solal-Céligny, Monica Bellei, Luigi Marcheselli, et al.
Pageof 19

Showing results (81-90 of 187) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortiumSonali M Smith, Koen van Besien, Theodore Karrison, et al.
Leukemia & Lymphoma|August 11, 2025
Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphomaEmily R Gordon, Seda Tolu, Brigit A Lapolla, et al.
British Journal of Haematology|July 5, 2007
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang, Luis Fayad, Peter McLaughlin, et al.
Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Yasuhiro Oki, Barbara Pro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
American Journal of Hematology|March 22, 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registryRobert N Stuver, Niloufer Khan, Marc Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantationMaricer P Escalón, Richard E Champlin, Rima M Saliba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsFarhad Ravandi, Ahmed Aribi, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study databasePhilippe Solal-Céligny, Monica Bellei, Luigi Marcheselli, et al.
Pageof 19